PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 05/15/24

2024-05-15 21:30:02 ET Citigroup analyst issues BUY recommendation for PRME on May 15, 2024 07:44PM ET. PRME was trading at $6.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold recommen...

2024-05-13 13:07:36 ET More on GameStop: GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come GameStop: Compelling Risk To Reward Profile Ahead Of Q4 Earnings GameStop's sudden mem...

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will partic...

2024-05-10 13:53:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prime Medicine (NASDAQ: PRME ) just reported results for the first quarter of 2024. Prime Medicine reported earnings per share of -44 cents. This was above the analyst est...

2024-05-10 08:06:25 ET More on Prime Medicine FDA clears Prime Medicine to begin gene therapy clinical testing Prime Medicine down 5%, prices $140M stock offering Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicin...

-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LN...

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial ...

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime ...

2024-04-29 16:11:48 ET More on Prime Medicine Prime Medicine down 5%, prices $140M stock offering Prime Medicine stock falls on proposed public offering of common stock Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime M...

First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, In...